상세정보
Export to Refworks부가기능
Managed entry agreements and funding for expensive therapies/ First edition
상세 프로파일
| 자료유형 | 단행본 |
|---|---|
| 서명/저자사항 | Managed entry agreements and funding for expensive therapies/ Mondher Toumi, Szymon Jaroslawski. |
| 개인저자 | Toumi, Mondher,author. Jaroslawski, Szymon,author, |
| 판사항 | First edition. |
| 형태사항 | 1 online resource. |
| 총서사항 | Pharmaceuticals, health economics and market access |
| 기타형태 저록 | Print version: Toumi, Mondher. Managed entry agreements and funding for expensive therapies First edition. Boca Raton : CRC Press, 2022 9780367500269 |
| ISBN | 9781000594676 100059467X 9781003048565 1003048560 9781000594638 1000594637 |
| 서지주기 | Includes bibliographical references and index. |
| 내용주기 | Introduction to managed entry agreements -- From coverage with evidence development to individual performance-based agreements in Italy -- Coverage with evidence development for multiple sclerosis drugs in the UK -- a "costly failure"? -- Novel funding models for expensive therapies -- Definition and classification of MEAs -- Country comparison of the implementation of managed entry agreements. |
| 요약 | "Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"-- |
| 해제 | Provided by publisher. |
| 일반주제명 | Medical care --Cost control. Drugs --Testing. Drugs --Prices. Drug accessibility. |
| 언어 | 영어 |
| 바로가기 |  |
